Key facts
- It has raised $227.0M across 1 recorded rounds; the latest was Later Stage VC (Series E) ($105.0M) in Jul 2024.
- Notable investors include Viking Global Investors, RA Capital Management, New Enterprise Associates, OrbiMed, Novo Holdings — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Magenta Medical
Funding rounds
1 roundsAbout Magenta Medical
Developer of medical devices designed to treat acute decompensated heart failure. The company's devices include a self-expanding heart pump and catheter-based therapy which addresses a pathophysiological core element of acute heart failures such as renal venous congestion and its deleterious effects on renal and cardiac function, enabling cardiac doctors to manage the congestion of their patients through quicker and safer fluid and salt removal while protecting and potentiating kidney function.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Kadima, Israel
- Founded
- 2012
- Employees
- 96
- Website
- magentamed.com/
- Ownership
- Privately Held (backing)
Magenta Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Magenta Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Magenta Medical in its N-PORT filings yet. We sweep new filings monthly.